Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$2.93 -8.7%	$2.97	$0.40 ▼ $5.48	$68.98M	0.27	465,514 shs	130,607 shs
BFRG Bullfrog AI	$1.23 -3.1%	$1.46	$1.17 ▼ $4.84	$12.40M	0.47	518,103 shs	92,508 shs
PRLD Prelude Therapeutics	$1.27 +2.4%	$0.87	$0.61 ▼ $5.64	$71.88M	1.22	193,643 shs	634,228 shs
STTK Shattuck Labs	$0.99 +3.5%	$0.86	$0.69 ▼ $3.95	$47.60M	1.63	844,824 shs	533,057 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	0.00%	-2.73%	+6.64%	+179.13%	+348.89%
BFRG Bullfrog AI	0.00%	+1.60%	-16.45%	-31.35%	-50.39%
PRLD Prelude Therapeutics	0.00%	+42.53%	+33.33%	+39.92%	-76.91%
STTK Shattuck Labs	0.00%	-4.00%	+13.45%	-11.11%	-72.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVC ABVC BioPharma	0.5097 of 5 stars	0.0	3.0	2.8	0.8	0.0
BFRG Bullfrog AI	0.3922 of 5 stars	0.0	3.0	0.6	2.5	0.0
PRLD Prelude Therapeutics	2.7804 of 5 stars	3.5	3.0	0.9	3.3	0.6
STTK Shattuck Labs	3.4949 of 5 stars	3.4	5.0	2.4	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	0.00	N/A	N/A	N/A
BFRG Bullfrog AI	0.00	N/A	N/A	N/A
PRLD Prelude Therapeutics	3.00	Buy	$4.00	214.96% Upside
STTK Shattuck Labs	2.83	Moderate Buy	$7.00	604.44% Upside

Current Analyst Ratings Breakdown

Latest BFRG, PRLD, ABVC, and STTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	PRLD Prelude Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$4.00 ➝ $3.00
8/14/2025	STTK Shattuck Labs	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$4.00 ➝ $2.00
8/14/2025	STTK Shattuck Labs	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	$391.24K	176.31	N/A	N/A	$0.06 per share	48.83
BFRG Bullfrog AI	$33.26K	372.84	N/A	N/A	$0.57 per share	2.16
PRLD Prelude Therapeutics	$7M	10.27	N/A	N/A	$2.39 per share	0.53
STTK Shattuck Labs	$5.72M	8.32	N/A	N/A	$1.67 per share	0.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$4.90M	-$0.17	N/A	∞	N/A	-963.46%	-46.76%	-23.02%	11/12/2025 (Estimated)
BFRG Bullfrog AI	-$6.99M	-$0.76	N/A	∞	N/A	N/A	-195.35%	-162.37%	N/A
PRLD Prelude Therapeutics	-$127.17M	-$1.64	N/A	N/A	N/A	N/A	-106.50%	-79.07%	11/5/2025 (Estimated)
STTK Shattuck Labs	-$75.41M	-$1.21	N/A	N/A	N/A	N/A	-81.80%	-71.46%	11/13/2025 (Estimated)

Latest BFRG, PRLD, ABVC, and STTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PRLD Prelude Therapeutics	-$0.45	-$0.41	+$0.04	-$0.41	N/A	N/A
8/14/2025	Q2 2025	STTK Shattuck Labs	-$0.25	-$0.24	+$0.01	-$0.24	N/A	N/A
8/13/2025	Q2 2025	ABVC ABVC BioPharma	N/A	-$0.13	N/A	-$0.13	N/A	N/A
8/13/2025	Q2 2025	BFRG Bullfrog AI	N/A	-$0.15	N/A	-$0.15	N/A	$0.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
BFRG Bullfrog AI	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.42	0.42
BFRG Bullfrog AI	N/A	3.97	3.97
PRLD Prelude Therapeutics	N/A	3.68	3.68
STTK Shattuck Labs	N/A	10.25	10.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
BFRG Bullfrog AI	0.96%
PRLD Prelude Therapeutics	79.72%
STTK Shattuck Labs	58.74%

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	17.10%
BFRG Bullfrog AI	24.72%
PRLD Prelude Therapeutics	63.90%
STTK Shattuck Labs	12.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	23.54 million	19.52 million	Not Optionable
BFRG Bullfrog AI	4	10.08 million	7.59 million	Not Optionable
PRLD Prelude Therapeutics	120	56.60 million	20.43 million	Optionable
STTK Shattuck Labs	100	47.90 million	42.16 million	Optionable

BFRG, PRLD, ABVC, and STTK Headlines

Recent News About These Companies

Shattuck Labs, Inc.: Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

August 22 at 10:45 AM | finanznachrichten.de

Shattuck Labs says IND for SL-325 for treatment of IBD in effect

August 22 at 10:45 AM | msn.com

Shattuck Labs Reports Q2 2025 Financial Results

August 22 at 10:45 AM | msn.com

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

August 21, 2025 | globenewswire.com

Shattuck Labs raises up to $103M to fund therapeutic antibody development

August 19, 2025 | ncbiotech.orgN

Shattuck Labs, Inc. (NASDAQ:STTK) Given Average Recommendation of "Moderate Buy" by Brokerages

August 19, 2025 | americanbankingnews.com

Leerink Partnrs Estimates Shattuck Labs Q1 Earnings

August 18, 2025 | americanbankingnews.com

Shattuck Labs' (STTK) "Hold" Rating Reiterated at Needham & Company LLC

August 17, 2025 | americanbankingnews.com

Shattuck Labs (NASDAQ:STTK) Price Target Lowered to $2.00 at Leerink Partners

August 16, 2025 | americanbankingnews.com

Shattuck Labs price target lowered to $2 from $4 at Leerink

August 14, 2025 | msn.com

Shattuck Labs Submits IND Application for SL-325; Phase 1 Trial in Healthy Volunteers Expected to Begin Q3 2025

August 14, 2025 | quiverquant.comQ

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 14, 2025 | globenewswire.com

Shattuck Labs expects $103 million from private placing

August 6, 2025 | thepharmaletter.comT

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

August 5, 2025 | globenewswire.com

Shattuck Labs Elects Directors, Approves Auditor at Meeting

July 15, 2025 | tipranks.com

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

July 2, 2025 | globenewswire.com

Shattuck Labs, Inc. (STTK) - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

June 13, 2025 | finance.yahoo.com

Shattuck Labs Advances SL-325 Program Amid Financial Progress

May 5, 2025 | tipranks.com

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRG, PRLD, ABVC, and STTK Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$2.93 -0.28 (-8.72%)

Closing price 04:00 PM Eastern

Extended Trading

$2.96 +0.03 (+1.19%)

As of 07:31 PM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Bullfrog AI NASDAQ:BFRG

$1.23 -0.04 (-3.15%)

Closing price 04:00 PM Eastern

Extended Trading

$1.23 0.00 (0.00%)

As of 07:59 PM Eastern

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

Prelude Therapeutics NASDAQ:PRLD

$1.27 +0.03 (+2.42%)

Closing price 04:00 PM Eastern

Extended Trading

$1.24 -0.03 (-2.36%)

As of 07:57 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Shattuck Labs NASDAQ:STTK

$0.99 +0.03 (+3.51%)

Closing price 04:00 PM Eastern

Extended Trading

$0.98 -0.02 (-1.88%)

As of 07:50 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time